| Semaglutide and cardiovascular outcomes in patients with type 2 diabetes SP Marso, SC Bain, A Consoli, FG Eliaschewitz, E Jódar, LA Leiter, ... New England Journal of Medicine 375 (19), 1834-1844, 2016 | 5202 | 2016 |
| Once-weekly semaglutide in adults with overweight or obesity JPH Wilding, RL Batterham, S Calanna, M Davies, LF Van Gaal, I Lingvay, ... New England Journal of Medicine 384 (11), 989-1002, 2021 | 1861 | 2021 |
| Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes M Husain, AL Birkenfeld, M Donsmark, K Dungan, FG Eliaschewitz, ... New England Journal of Medicine 381 (9), 841-851, 2019 | 1370 | 2019 |
| Cardiac Steatosis in Diabetes Mellitus: A 1H-Magnetic Resonance Spectroscopy Study JM McGavock, I Lingvay, I Zib, T Tillery, N Salas, R Unger, BD Levine, ... Circulation 116 (10), 1170-1175, 2007 | 706 | 2007 |
| Semaglutide 2· 4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial M Davies, L Færch, OK Jeppesen, A Pakseresht, SD Pedersen, ... The Lancet 397 (10278), 971-984, 2021 | 613 | 2021 |
| Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial RE Pratley, VR Aroda, I Lingvay, J Lüdemann, C Andreassen, A Navarria, ... The lancet Diabetes & endocrinology 6 (4), 275-286, 2018 | 581 | 2018 |
| Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial D Rubino, N Abrahamsson, M Davies, D Hesse, FL Greenway, C Jensen, ... Jama 325 (14), 1414-1425, 2021 | 566 | 2021 |
| 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023 NA ElSayed, G Aleppo, VR Aroda, RR Bannuru, FM Brown, D Bruemmer, ... Diabetes Care 46 (Supplement_1), S140-S157, 2023 | 515 | 2023 |
| Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical … TA Wadden, TS Bailey, LK Billings, M Davies, JP Frias, A Koroleva, ... Jama 325 (14), 1403-1413, 2021 | 489 | 2021 |
| Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial AJ Ahmann, M Capehorn, G Charpentier, F Dotta, E Henkel, I Lingvay, ... Diabetes care 41 (2), 258-266, 2018 | 454 | 2018 |
| Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial R Pratley, A Amod, ST Hoff, T Kadowaki, I Lingvay, M Nauck, ... The Lancet 394 (10192), 39-50, 2019 | 404 | 2019 |
| Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial HW Rodbard, J Rosenstock, LH Canani, C Deerochanawong, ... Diabetes care 42 (12), 2272-2281, 2019 | 334 | 2019 |
| Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation I Lingvay, P Sumithran, RV Cohen, CW le Roux The Lancet 399 (10322), 394-405, 2022 | 303 | 2022 |
| Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial HW Rodbard, I Lingvay, J Reed, R De La Rosa, L Rose, D Sugimoto, ... The Journal of Clinical Endocrinology & Metabolism 103 (6), 2291-2301, 2018 | 291 | 2018 |
| Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized … I Lingvay, FP Manghi, P García-Hernández, P Norwood, L Lehmann, ... Jama 315 (9), 898-907, 2016 | 280 | 2016 |
| Serum urate lowering with allopurinol and kidney function in type 1 diabetes A Doria, AT Galecki, C Spino, R Pop-Busui, DZ Cherney, I Lingvay, ... New England Journal of Medicine 382 (26), 2493-2503, 2020 | 270 | 2020 |
| Noninvasive quantification of pancreatic fat in humans I Lingvay, V Esser, JL Legendre, AL Price, KM Wertz, B Adams-Huet, ... The Journal of Clinical Endocrinology & Metabolism 94 (10), 4070-4076, 2009 | 253 | 2009 |
| Semaglutide and cardiovascular outcomes in obesity without diabetes AM Lincoff, K Brown-Frandsen, HM Colhoun, J Deanfield, SS Emerson, ... New England Journal of Medicine 389 (24), 2221-2232, 2023 | 235 | 2023 |
| Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension JPH Wilding, RL Batterham, M Davies, LF Van Gaal, K Kandler, K Konakli, ... Diabetes, Obesity and Metabolism 24 (8), 1553-1564, 2022 | 227 | 2022 |
| Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5 RF Kushner, S Calanna, M Davies, D Dicker, WT Garvey, B Goldman, ... Obesity 28 (6), 1050-1061, 2020 | 220 | 2020 |
Professor Melanie J DaviesDiabetes Research Centre, University of LeicesterVerified email at uhl-tr.nhs.uk
